The Staudt laboratory has conducted RNA interference genetic screens for genes required for the proliferation and/or survival of human cell lines representing various subtypes of lymphoma and multiple myeloma. In diffuse large B cell lymphoma (DLBCL), previous work in the Staudt laboratory demonstrated that the anti-apoptotic NF-kB pathway is constitutively active in the activated B cell-like (ABC) subtypes of DLBCL but not the germinal center B cell-like (GCB) subtype of DLBCL, but the mechanisms underlying this abnormal signaling were enigmatic. The laboratory therefore conducted an RNAi screen in ABC and GCB DLBCL cell lines, searching for shRNAs that were selectively toxic for ABC DLBCL cells. This effort revealed that a signaling complex comprised of CARD11, MALT1, and BCL10 is required for the survival of ABC but not GCB DLBCL cell lines. In normal lymphocytes, this CARD11 complex engages the NF-kB pathway during antigen receptor signaling. The Staudt laboratory demonstrated that this signaling complex is responsible for the constitutive activation of the NF-kB pathway in ABC DLBCLs. In a recent RNA interference screen we identified several shRNAs targeting casein kinase 1A1 (CK1α) that were toxic for ABC but not GCB DLBCL cell lines. Since this phenotype resembled the toxicity profile of CARD11 shRNAs, we suspected that CK1αmight be a new component of the CBM signaling pathway. Indeed, CK1αknockdown decreased IKK kinase activity and NF-kB target gene expression, and CK1αcolocalized with CARD11 in ABC DLBCL cell lines. Fortuitously, Mike Lenardo's laboratory in NIAID separately identified CK1α as a binding partner of CARD11 in a mass spectrometry-based screen. Collaborative experiments revealed the essential role of CK1αin T cell receptor activation of the NF-kB pathway. Biochemically, CK1αwas required for the recruitment of IKK to the CBM complex. Interestingly, T cells reconstituted with a CK1αmutant that was defective in kinase activity provided a greater NF-kB stimulus than did wild type CK1α, demonstrating that CK1αhas both positive and negative influences on the CBM pathway. The negative effect of CK1αwas due to its phosphorylation of CARD11 on serines in its """"""""linker"""""""" domain, causing CARD11 to be destabilized. This negative feedback loop involving CK1αwas analogous to the negative regulation of the CBM complex caused by inhibitory phosphorylation of BCL10 by IKK. CK1αemerged from this study as a new component of the CBM, demonstrating the power of unbiased RNA interference screens to uncover overlooked aspects of cellular signaling. A recent RNAi screen uncovered a crucial dependency of multiple myeloma cells on IRF4, a lymphoid-restricted transcriptional factor that is required for both lymphocyte activation and for plasmacytic differentiation. IRF4 knockdown by RNAi was toxic to 10 different myeloma cell lines representing many of the known genetic subtypes of this cancer. Of note, IRF4 is not translocated, amplified or mutated in most cases of multiple myeloma, and thus the dependency of myeloma cells on IRF4 exemplifies a new concept in cancer biology known as non-oncogene addiction. These results establish IRF4 as an important new therapeutic target in this lethal cancer.
| Nakagawa, Masao; Shaffer 3rd, Arthur L; Ceribelli, Michele et al. (2018) Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. Cancer Cell 34:286-297.e10 |
| Phelan, James D; Young, Ryan M; Webster, Daniel E et al. (2018) A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature 560:387-391 |
| Ceribelli, Michele; Hou, Zhiying Esther; Kelly, Priscilla N et al. (2016) A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell 30:764-778 |
| Hodson, Daniel J; Shaffer, Arthur L; Xiao, Wenming et al. (2016) Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Natl Acad Sci U S A 113:E2039-46 |
| Rui, Lixin; Drennan, Amanda C; Ceribelli, Michele et al. (2016) Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 113:E7260-E7267 |
| Ceribelli, Michele; Kelly, Priscilla N; Shaffer, Arthur L et al. (2014) Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 111:11365-70 |
| Sanda, Takaomi; Tyner, Jeffrey W; Gutierrez, Alejandro et al. (2013) TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 3:564-77 |
| Lamy, Laurence; Ngo, Vu N; Emre, N C Tolga et al. (2013) Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 23:435-49 |
| Yeung, C L; Ngo, V N; Grohar, P J et al. (2013) Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene : |
| Yang, Yibin; Shaffer 3rd, Arthur L; Emre, N C Tolga et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723-37 |
Showing the most recent 10 out of 20 publications
